The Pharma-Grade Cannabis Formulas engagement, the only exclusivity tier in the Canalytics suite, gives a cannabis-derived therapeutic program its full analytical infrastructure on day one. Receptor-level pharmacology, multi-pathway mechanism analysis, drug interaction modeling, target chemovar specification, clinical-trial-grade decision support and delivered in direct partnership with the scientific team that built the engine. No years of internal build required.
The sponsor operates with the analytical infrastructure that would otherwise require years of internal team build, on a deterministic engine whose every output can be traced for a regulatory submission.
A pharmaceutical-depth cannabis pharmacology reference has not existed as a single consolidated resource. Target specification, genetic sourcing, breeding validation and production managed across separate partners introduces coordination overhead, IP exposure and timeline complexity. Clinical trial sites without a consistent decision support layer produce variable outputs across sites. Documentation assembled manually from primary literature is resource-intensive and difficult to standardize for submission.
Target receptor engagement, effect scoring, pharmacokinetic constraints and interaction profile translated into a chemovar specification. Natural genetics screened against it. Canalytics Breeding Software simulations identifying the crosses most likely to produce it. Multi-site trials on one recommendation engine. Every output carrying compound, pathway, source, evidence strength and peer-review status for the submission.
Specify the target, screen the genetics, direct the breeding, validate in the clinic, document for the IND. One engine, one partnership, one defensible record.
Five core deliverables, available exclusively at the Pharma-Grade tier
Canalytics works with each sponsor to specify the therapeutic target at pharmaceutical depth: receptor engagement, target scores across the effect framework, contraindication flags, pharmacokinetic constraints and contraindicated interaction profiles. That specification is translated into the cannabinoid profile, terpene profile, ratio constraints and secondary compound considerations the development pipeline targets from program initiation.
Plant Match searches any genetic library — including the cultivator and breeder network operating on Canalytics — for genetics whose cannabinoid and terpene ratios most closely match the target specification, including designer profiles reverse-engineered from the research literature. Quantified similarity scores with a per-compound breakdown identify the closest natural source material before committing to a development path.
Cancer Chemovar Alignment evaluates chemovars across multiple weighted pathways and cancer types — identifying which cannabinoid and terpene concentrations clinical research has most consistently associated with each cancer category. Documented cannabinoid-terpene synergy pairs, potentiation factors, ML clustering, dimensionality reduction and feature importance analysis reveal the compound-level drivers behind each alignment score.
Canalytics Breeding Software simulations identify the parent crosses and ratios most likely to produce the target chemovar. The breeder and cultivator partner network provides production capability aligned to the sponsor's specification through the analytical layer, reducing coordination overhead and IP exposure.
The Cannabis Clinical Suite gives trial sites a validated, consistent decision support layer: NIH-validated assessment intake, per-condition scoring, drug interaction analysis with contraindication flags and HIPAA-grade architecture. EMR-independent deployment standardizes output across international multi-site networks.
Mechanism of action with receptor-level depth, drug interaction profiles, contraindication identification, pharmacological synergy modeling and clinical decision support validation, each supported by a robust study database with evidence strength and peer-review status. Deterministic outputs, not black-box generation. Aligned to FDA 21 CFR Part 11 and ICH E6 GCP.
Pharmaceutical sponsors deploy at the deepest analytical tier across the suite, with bespoke target chemovar specification and the cancer chemovar alignment framework at the center.
Ten weighted pathways, 15+ cancer types, synergy modeling and the full ML analytics suite — identifying research-aligned chemovar profiles for each cancer category.
Search the full genetic universe for natural chemovars matching a pharmaceutical-grade cannabinoid and terpene specification developed in partnership with Canalytics.
Receptor mapping, strain comparison and clinical NIH-validated assessment workflows.
Canalytics Breeding Software simulation directing crosses toward the target chemovar.
Standardized recommendation and safety screening across trial sites.
Multi-cohort outcome comparison across sites and populations.
Time, traceability, and a partnership with the team behind the engine
Target specification, source screening and breeding direction that previously ran as separate multi-cycle engagements become a structured workflow on one analytical layer. The pharmacology reference and documentation pipeline that would take years to build internally are in place at engagement start.
Regulatory teams need to show where each mechanism, interaction and synergy claim came from. Because the Canalytics engine is deterministic and supported by a robust study database, every output carries evidence strength and peer-review status. There is no black-box step to explain away.
AES-256 PHI encryption with rotating keys, audit logs, MFA, retention policy enforcement, role-based access and documented consent workflows, aligned to HIPAA, FDA 21 CFR Part 11, ICH E6 GCP, GDPR, LGPD and LFPDPPP. Multi-site international trials run on the same engine with consistent, defensible output at every site.
The Pharma-Grade tier includes co-development, custom analytical modules and dedicated research support from the team that built the scoring engine and the 20+ year research base beneath it. This is the only exclusivity offering in the Canalytics model.
Four stages from target specification to regulatory submission
Canalytics works with the sponsor to define the therapeutic target: receptor engagement, effect scoring, PK constraints and interaction profile. The output is a bespoke chemovar specification the pipeline builds against.
Plant Match searches the genetic universe for natural chemovars whose cannabinoid and terpene ratios best match the target specification. Canalytics Breeding Software identifies the crosses most likely to produce it. The partner network aligns production to the target.
Multi-site trials run on the Cannabis Clinical Suite with standardized NIH-validated assessment intake, per-condition scoring and interaction screening, on trial-ready architecture.
Documentation of mechanism, interactions, synergy and decision support validation is generated for the regulatory submission, with every claim supported by a robust study database.
The infrastructure of a cannabis-derived therapeutic program, delivered as a partnership
Every product Canalytics analyzes is scored across 30 therapeutic and adult use effects on a 0 to 10 scale, from the full cannabinoid and terpene fingerprint in its COA. This is the shared vocabulary that lets a breeder target an effect, a dispensary sort a shelf by it, a marketer write to it, and a clinician recommend against it.
Condition-relevant effects scored from receptor-level pharmacology, so clinical positioning and evidence-aligned recommendations rest on science.
Experience-relevant effects that predict how a product actually feels, so customers can shop by outcome instead of by strain name and THC percentage.
Beyond the effects shown above, Canalytics scores 17 additional therapeutic and adult use effects on every product, delivering the most complete effect profile in the industry and the depth needed to filter for what a customer wants and against what they want to avoid.
Every effect is quantified, not described. Products become sortable, comparable and rankable against any target.
Find high Calm and low Couchlock, or Focus without Anxiety. Score for the effects wanted and against the effects to avoid.
Cannabinoids and terpenes mapped to CB1, CB2, TRPV1, 5-HT1A, PPARγ, opioid μ and more, so scores rest on mechanism.
Every score is supported by a robust study database of peer-reviewed research. No black box.
For pharmaceutical sponsors with active or planned cannabis-derived therapeutic programs, the engagement begins with a confidential briefing against your specific therapeutic platform and pipeline.
Begin with a confidential Strategic Briefing, followed by a discussion of SaaS service options for subscribing to Canalytics' services — deploying bespoke target chemovar specification and multi-pathway analytics against your highest-priority development asset. Full Pharma-Grade engagement is scoped from there.